2483-51-4

Basic information

• Product Name: Z-ALA-ALA-OME
• Synonyms: Z-L-ALANYL-L-ALANINE METHYL ESTER;Z-ALA-ALA-OME;Cbz-Ala-Ala-OMe;Cbz-L-Ala-L-Ala-OMe
• CAS NO: 2483-51-4
• Molecular Formula: C₁₅H₂₀N₂O₅
• Molecular Weight: 308.33
• EINECS: 1533716-785-6
• Mol File: 2483-51-4.mol
• Article Data: 30

Chemical Properties

• Melting Point: 93-94 °C
• Appearance: /
• Storage Temp.: -15°C
• CAS DataBase Reference: Z-ALA-ALA-OME(CAS DataBase Reference)
• NIST Chemistry Reference: Z-ALA-ALA-OME(2483-51-4)
• EPA Substance Registry System: Z-ALA-ALA-OME(2483-51-4)

Safety Data

• Hazardous Substances Data: 2483-51-4(Hazardous Substances Data)

Usage

General Description

Z-ALA-ALA-OME is a synthetic chemical compound that is composed of two molecules of the amino acid alanine (ALA) linked together, followed by an ome group. The prefix "Z" indicates that the compound has a cis configuration, which means that the two alanine molecules are oriented in the same direction. Z-ALA-ALA-OME is often used in research and pharmaceutical development as a substrate for studying enzyme activity and peptide synthesis. Its structure and properties make it a valuable tool for studying the biological and biochemical functions of amino acids and peptides in various experimental contexts.

Upstream product

• 2491-20-5 L-alanine methyl ester hydrochloride 
• 3401-36-3 (N-benzyloxycarbonyl)-L-alanine N-hydroxysuccinimide ester 
• 4132-86-9 N-benzyloxycarbonylalanine 
• 65638-93-9 N-Carbobenzoxy-L-alanin-kohlensaeureaethylesteranhydrid 
• 133010-19-2 (S)-N-cbz-alanoyl fluoride 
• 501-53-1 benzyl chloroformate 
• 1142-20-7 N-Cbz-Ala 
• 10065-72-2 L-Alanine methyl ester 
• 210840-42-9 N-(Benzyloxycarbonyl)alanine (3,5-di-tert-butyl-4-hydroxyphenyl)ester 
• 186581-53-3 diazomethane 
• 122751-37-5 Z-Ala-OPyCl 
• 26607-52-3 Cbz-Ala-OH*DCHA 
• 1168-87-2 benzyloxycarbonylalanine p-nitrophenyl ester 
• 67-56-1 methanol 

Downstream Products

• 16012-70-7 benzyloxycarbonyl-L-alanyl-L-alanine 
• 5625-46-7 (+/-)-cis-3,6-dimethyl-piperazine-2,5-dione 
• 41036-19-5 L-alanyl-alanine methylester hydrochloride 
• 87043-02-5 Z-L-Ala-ψ(CSNH)-L-Ala-OMe 
• 95205-40-6 mononitrosated benzoxycarbonylalanylalanine methyl ester 
• 95205-39-3 dinitrosated benzoxycarbonylalanylalanine methyl ester 
• 5845-61-4 cyclo(L-Ala-L-Ala) 
• 132329-82-9 Z-Ala-Ala-Ala-Aib-Aib-OMe 
• 1604809-89-3 Z-Azt(tBu)-Ala-Ala-OMe, Azt - 3-aminoazetidine-3-carboxylic acid 
• 1604809-90-6 Z-Azt(tAmyl)-Ala-Ala-OMe 
• 35766-23-5 Cbz-Ala-Ala-Gly-O-t-Bu 
• 129221-00-7 benzyl ((S)-1-(((S)-1-hydroxypropan-2-yl)amino)-1-oxopropan-2-yl)carbamate 

Relevant articles and documents

HIGH OXIDATION STATE TRANSITION METAL CARBOXYLATES AS ACYLATING AGENTS

The formation of amide bonds from the reaction of metal carboxylates with amines was observed for the first time; complexes for titanium(IV), zirconium(IV) and tantalum(V) were investigated.

Metal-free approach for hindered amide-bond formation with hypervalent iodine(iii) reagents: application to hindered peptide synthesis

A new bio-inspired approach is reported for amide and peptide synthesis using α-amino esters that possess a potential activating group (PAG) at the ester residue. To activate the ester functionality under mild metal-free conditions, we exploited the facile dearomatization of phenols with hypervalent iodine(iii) reagents. Using a pyridine-hydrogen fluoride complex, highly reactive acyl fluoride intermediates can be successfully generated, thereby allowing for the smooth formation of sterically hindered amides and peptides from bulky amines and α-amino esters, respectively.

Legumain Activated Doxorubicin Derivative as well as Preparation Method and Application Thereof

The present invention discloses doxorubicin derivatives for targeted activation by Legumain, its preparation method and use. The doxorubicin derivatives are obtained by condensation between the amino group of compound A and the carboxyl group of compound B and have the following structure: compounds A and B have the following structures, respectively: wherein R3 in compound B is Leu or absent; R4 is any one amino acid selected from the group consisting of Ala and Thr; R5 is any one amino acid selected from the group consisting of Ala, Thr and Asn; R6 is wherein n=1-20; or wherein R7 is substituted or unsubstituted, linear or branched, saturated or unsaturated C1-C20 fatty hydrocarbon, or substituted or unsubstituted C6-C20 aromatic hydrocarbon. The doxorubicin derivatives of the present invention are specifically tumor-targeted and have a long in vivo metabolic half-life, as compared with doxorubicin. They exhibit an efficient and safe anti-tumor effect and could be used to prepare an anti-tumor drug.